ProQR (PRQR) Price & Analysis

Compare

1,119 Followers

PRQR Stock Chart & Stats

$2.46

-$0.10(-3.77%)

At close: Jan 08 4:00 PM EST

$2.46

-$0.10(-3.77%)

Day’s Range― - ―

52-Week Range$1.07 - $4.62

Previous CloseN/A

Volume75.97K

Average Volume (3M)416.89K

Market Cap

$253.56M

Enterprise Value$91.96M

Total Cash (Recent Filing)$119.77M

Total Debt (Recent Filing)$16.86M

Price to Earnings (P/E)―

Beta1.70

Next Earnings

Nov 05, 2025

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding105,212,524

10 Day Avg. Volume491,191

30 Day Avg. Volume416,892

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.36

Enterprise Value/Revenue5.58

Enterprise Value/Gross Profit5.58

Enterprise Value/Ebitda-2.58

Forecast

1Y Price Target

$8.25

Price Target Upside235.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsProQR's shift from preclinical promise to clinical execution marks an important step with AX-0810’s Clinical Trial Application.

Innovative Platform ValidationA two-fold reduction in bile acid levels might powerfully validate ProQR’s EON RNA editing platform by targeting NTCP.

Strategic PartnershipsStrategic alignment remains strong, with Eli Lilly expanding its partnership to 15 CNS/PNS targets and reaffirming confidence through direct equity participation.

Bears Say

Clinical TrialsThe company has submitted its clinical trial application to the EMA, with first-in-human dosing expected in the Netherlands and an initial Phase 1 dataset in Q4 2025.

Platform Expansion ChallengesThe advancement of AX-2402 for Rett syndrome introduces a high-value CNS indication, expanding the platform’s reach beyond hepatic targets.

ProQR News

ProQR Therapeutics Advances RNA Therapy Pipeline

ProQR Therapeutics BV ( ($PRQR) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

PRQR

ProQR’s Strategic Advancements and Promising RNA Editing Platform Earns Buy Rating

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ProQR, with a...

2M ago

PRQR

ProQR’s Strategic Advancements and Clinical Prospects Drive Buy Rating

In a report released on August 8, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ProQR,...

2M ago

PRQR

ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs

ProQR ( ($PRQR) ) has shared an announcement. On August 7, 2025, ProQR Therapeutics N.V. announced its financial...

2M ago

PRQR

ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year

Reports revenue EUR 3.8M vs. EUR 6.3M last year. “We continued to execute across our pipeline in the...

2M ago

PRQR

ProQR Therapeutics sees cash runway into mid-2027

At June 30, 2025, ProQR held cash and cash equivalents of approximately EUR 119.8 million, compared to EUR...

2M ago

PRQR

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

Evercore ISI raised the firm’s price target on ProQR Therapeutics (PRQR) to $5 from $4 and keeps an...

3M ago

PRQR

ProQR Submits CTA for Phase 1 Study of AX-0810

ProQR ( ($PRQR) ) just unveiled an update. On June 26, 2025, ProQR Therapeutics announced the submission of...

4M ago

PRQR

ProQR Shareholders Approve Key Resolutions at Annual Meeting

The latest announcement is out from ProQR ( ($PRQR) ). On June 3, 2025, ProQR Therapeutics N.V. held...

4M ago

PRQR

ProQR Therapeutics Reports Q1 2025 Financial Results

ProQR Therapeutics BV ( ($PRQR) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

PRQR

ProQR Therapeutics price target lowered to $9 from $15 at Oppenheimer

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on ProQR Therapeutics (PRQR) to $9 from $15 and...

5M ago

PRQR

ProQR’s Innovative RNA Editing Platform and Promising AX-0810 Program Drive Buy Rating

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on PRQR stock, giving a Buy rating on...

5M ago

PRQR

ProQR Reports Q1 2025 Financial Results Amid Rising R&D Costs

ProQR ( ($PRQR) ) has issued an announcement. ProQR Therapeutics N.V. announced its financial results for the first...

5M ago

PRQR

ProQR Therapeutics reports Q1 EPS (EUR 0.10) vs (EUR 0.09) last year

Reports Q1 revenue EUR 4.519M vs EUR 4.450M last year. “ProQR entered 2025 in a position of strength,...

5M ago

PRQR

PRQR FAQ

What was ProQR’s price range in the past 12 months?

ProQR lowest stock price was $1.07 and its highest was $4.62 in the past 12 months.

What is ProQR’s market cap?

ProQR’s market cap is $253.56M.

When is ProQR’s upcoming earnings report date?

ProQR’s upcoming earnings report date is Nov 05, 2025 which is in 21 days.

How were ProQR’s earnings last quarter?

ProQR released its earnings results on Aug 07, 2025. The company reported -$0.139 earnings per share for the quarter, the consensus estimate of -$0.139 by $0.

Is ProQR overvalued?

According to Wall Street analysts ProQR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ProQR pay dividends?

ProQR does not currently pay dividends.

What is ProQR’s EPS estimate?

ProQR’s EPS estimate is -0.12.

How many shares outstanding does ProQR have?

ProQR has 105,212,524 shares outstanding.

What happened to ProQR’s price movement after its last earnings report?

ProQR reported an EPS of -$0.139 in its last earnings report, expectations of -$0.139. Following the earnings report the stock price went down -0.485%.

Which hedge fund is a major shareholder of ProQR?

Currently, no hedge funds are holding shares in PRQR

ProQR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-75.99%

Trailing 12-Months

Asset Growth

27.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ProQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR (PRQR) Earnings & Revenues

Historic Earnings Reports

PRQR Stock 12 Month Forecast

Average Price Target

$8.25

▲(235.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,3.036923076923077,3.783846153846154,4.530769230769231,5.277692307692308,6.024615384615386,6.771538461538462,7.51846153846154,8.265384615384615,9.012307692307694,9.75923076923077,10.506153846153847,11.253076923076925,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.7484615384615383,3.206923076923077,3.6653846153846157,4.123846153846154,4.582307692307692,5.0407692307692304,5.49923076923077,5.957692307692308,6.416153846153846,6.874615384615384,7.3330769230769235,7.791538461538462,{"y":8.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.4984615384615383,2.706923076923077,2.9153846153846152,3.123846153846154,3.332307692307692,3.5407692307692304,3.749230769230769,3.957692307692308,4.166153846153846,4.374615384615384,4.5830769230769235,4.791538461538462,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.82,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >